ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » New York » Pulmonary Disease

Top Pulmonary Disease Prescribers in New York

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
ALVERIS MOLINA M.D.

Pulmonary Disease

24,048

$1.15M

715
591 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

17%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 56%

$48
Average prescription price

Avg: $126

THOMAS CHAN MD

Pulmonary Disease

19,715

$1.98M

859
809 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 56%

$101
Average prescription price

Avg: $126

WILFREDO TALAVERA M.D.

Pulmonary Disease

16,291

$1.05M

518
432 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

10%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 56%

$64
Average prescription price

Avg: $126

IQBAL SAMAD MD FRCP FCCP

Pulmonary Disease

14,469

$526K

377
243 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

44%
patients receiving schedule three controlled substances

Avg: 1%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 56%

$36
Average prescription price

Avg: $126

RAMKUMAR PANHANI MD

Pulmonary Disease

14,036

$791K

491
437 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 56%

$56
Average prescription price

Avg: $126

LUIS GUERRERO M.D.

Pulmonary Disease

13,774

$786K

647
535 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 56%

$57
Average prescription price

Avg: $126

JOHN WANG M.D.

Pulmonary Disease

13,062

$1.24M

510
463 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

47%
prescriptions for brand name drugs

Avg: 56%

$95
Average prescription price

Avg: $126

RAMEEN MIARROSTAMI MD

Pulmonary Disease

12,508

$1.01M

566
491 are 65+

2%
patients receiving schedule two controlled substances

Avg: 1%

2%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 56%

$80
Average prescription price

Avg: $126

MOHAN CHEEMA MD

Pulmonary Disease

11,976

$473K

576
522 are 65+

19%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 56%

$39
Average prescription price

Avg: $126

BORIS SAGALOVICH MD

Pulmonary Disease

11,316

$1.99M

1044
959 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

83%
prescriptions for brand name drugs

Avg: 56%

$175
Average prescription price

Avg: $126

ISRAEL SAMSON MD

Pulmonary Disease

10,098

$730K

566
482 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

37%
prescriptions for brand name drugs

Avg: 56%

$72
Average prescription price

Avg: $126

SERGIO MARTINEZ

Pulmonary Disease

9,418

$738K

708
569 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 56%

$78
Average prescription price

Avg: $126

RAKESH BHARDWAJ M.D.

Pulmonary Disease

9,169

$567K

490
430 are 65+

14%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 56%

$62
Average prescription price

Avg: $126

MOHAMMAD AKHTER M.D.

Pulmonary Disease

8,586

$499K

353
319 are 65+

15%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 56%

$58
Average prescription price

Avg: $126

RAVINDRA GOYAL MD

Pulmonary Disease

8,460

$565K

329
280 are 65+

7%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 56%

$67
Average prescription price

Avg: $126

JITENDRA TOLIA M.D.

Pulmonary Disease

8,452

$480K

320
294 are 65+

6%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 56%

$57
Average prescription price

Avg: $126

ARON RUBIN MD

Pulmonary Disease

8,002

$636K

258
237 are 65+

13%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

50%
prescriptions for brand name drugs

Avg: 56%

$79
Average prescription price

Avg: $126

JEFFREY VORSANGER M.D.

Pulmonary Disease

7,866

$677K

499
461 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 56%

$86
Average prescription price

Avg: $126

MICHAEL ABOTT MD

Pulmonary Disease

7,650

$557K

404
343 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 56%

$73
Average prescription price

Avg: $126

EDWARD FITZPATRICK MD

Pulmonary Disease

7,542

$574K

517
449 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 56%

$76
Average prescription price

Avg: $126

GARY GARFIELD DO

Pulmonary Disease

7,501

$566K

423
341 are 65+

11%
patients receiving schedule two controlled substances

Avg: 1%

7%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 56%

$76
Average prescription price

Avg: $126

RICHARD DUNCALF MD

Pulmonary Disease

7,294

$394K

194
144 are 65+

9%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 56%

$54
Average prescription price

Avg: $126

JASON KARP MD

Pulmonary Disease

7,251

$2.11M

983
895 are 65+

1%
patients receiving schedule two controlled substances

Avg: 1%

1%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

62%
prescriptions for brand name drugs

Avg: 56%

$290
Average prescription price

Avg: $126

EUGENE GIBILARO M.D.

Pulmonary Disease

7,225

$369K

463
416 are 65+

16%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 56%

$51
Average prescription price

Avg: $126

GILBERT WITTE M.D.

Pulmonary Disease

7,139

$1.03M

573
469 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

57%
prescriptions for brand name drugs

Avg: 56%

$145
Average prescription price

Avg: $126

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank